Navigating the Future of Healthcare: IP Strategies, Regulatory Challenges and Beyond
Copenhagen, Denmark
02 October 2025 - 04 October 2025
Navigating the Future of Healthcare: IP Strategies, Regulatory Challenges and Beyond
Thursday 02 October 2025 | |
| 17:00 | Resgistrations open |
| 18:00 » 20:00 | Welcome reception More information will soon be share |
| 20:00 | Optional dinner More information will soon be shared |
Friday 03 October 2025 | |
| 08:30 | Registrations open at Tivoli Hotel
|
| 09:15 » 09:30 | Opening session |
| 09:30 » 10:00 | Keynote speech |
| 10:00 » 11:00 | Panel 1: The EU pharmaceutical package: The hot topics What are the key elements of the upcoming EU pharmaceutical package, focusing on its impact on healthcare, innovation, and regulatory harmonisation? What is the role of digital transformation in driving AI and data innovation in life sciences? |
| 11:00 » 11:30 | Coffee Break |
| 11:30 » 12:30 | Panel 2: Tele-Medicine What are the regulatory frameworks for telemedicine, and how do they impact innovation and IP protection? What are the key IP considerations for telemedicine technologies? How does GDPR affect data privacy in telemedicine? What measures can ensure data security and patient confidentiality? How can telemedicine services be promoted in compliance with national regulations? |
| 12:30 » 14:00 | Lunch break |
| 14:00 » 15:00 | Panel 3: AI x IP x Life Sciences What are the IP challenges and opportunities for AI-driven innovations in life sciences, such as AI-powered drug discovery and personalized medicine? What legal rules apply to 3D-printed health science products? Who owns the IP rights to AI-generated inventions, especially in collaborative settings? How does GDPR impact the development and commercialisation of AI-driven solutions in life sciences? |
| 15:00 » 16:00 | Panel 4: Navigating Cross-Border Health Data Flow How do global regulatory frameworks affect the flow of health data across borders, and what challenges arise for healthcare organisations? How can data be transferred within the EU and to countries like the UK and US? How are emerging technologies reshaping cross-border data transfer, and what challenges and opportunities do they bring? What are the key considerations for drafting cross-border data transfer agreements to ensure compliance? |
| 16:00 » 16:30 | Coffee break |
| 16:30 » 17:30 | Panel 5: Unpacking Repackaging and Relabelling in Pharmaceuticals What are the legal and regulatory requirements for repackaging and relabelling pharmaceuticals, and how do they differ across jurisdictions? What IP considerations, such as patent rights and trademark protection, are involved? What are the potential product liability risks, and how can they be mitigated? How does repackaging relate to parallel importation, and what legal challenges arise? How do companies approach branding and marketing of repackaged products while maintaining compliance? |
| 20:00 | Dinner More information to follow |
Saturday 04 October 2025 | |
| 09:30 » 01:00 | Registrations open at Tivoli Hotel
|
| 10:00 » 11:00 | Panel 6: eHealth Entrepreneurship - How to start and grow a Digital Health StartUp What strategies should life science startups use to identify and protect their IP early on? How can startups leverage IP licencing and collaborations to accelerate innovation and generate revenue? What best practices should be followed for managing IP portfolios, including optimisation, cost management, and strategic patent decisions? |
| 11:00 » 11:30 | Coffe break |
| 11:30 » 12:30 | Panel 7: Online influencers, digital media, and pharmaceutical advertisement Are current laws clear and ready to address innovative approaches like AI, social media, and influencer endorsements in pharmaceutical advertising? How does the regulation of audiovisual media services impact advertising in the life sciences? What unique challenges do influencers face when promoting pharmaceuticals, medical devices, or dietary supplements? |
| 12:30 » 13:30 | Panel 8: Impact of patent protection and market exclusivity on reimbursement of pharmaceuticals How do different jurisdictions enforce patents, RDP, and market exclusivity? How do pricing and reimbursement authorities consider potential IP violations? Should there be public enforcement of market exclusivity? What is the scope of RDP protection after the ECJ judgment C-438/21 P, and how far will it extend |
| 13:30 » 13:45 | Closing remarks |
| 13:45 » 15:00 | Lunch |
| 16:00 | Optional activity and optional dinner
|